Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Protection against severe COVID-19 illness, hospitalization, and death tends to hold up well for at least six months to a year after vaccination, while protection against mild or asymptomatic infection often begins fading within two to four months. How long your own protection lasts depends on your age, immune health, which vaccine or booster you received, how recently you were infected, and which variants are circulating, so there are several important factors to consider below. Because waning immunity can look a lot like a new infection starting, symptoms such as fatigue, sore throat, cough, or fever deserve attention rather than guesswork. If you are feeling unwell and unsure whether it is COVID, another respiratory virus, or something unrelated, a free, instant, online symptom check can help you organize what you are experiencing and understand possible causes in minutes. Use it to clarify your next steps, including whether testing or a visit with a clinician makes sense now.
Last reviewed for medical accuracy: 09/23/2026
Understanding how long the COVID-19 vaccine protects you can help you make informed decisions about boosters, travel, work and daily life. Here’s a clear overview based on data from the U.S. Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and peer-reviewed studies.
These layers of protection don’t all last the same amount of time. In general, vaccines give stronger, longer-lasting defense against severe outcomes than against mild or asymptomatic infection.
Most studies focus on mRNA vaccines (Pfizer-BioNTech and Moderna), with some data on viral-vector vaccines (Johnson & Johnson).
Bottom line: Without a booster, your protection against infection typically falls significantly after 4–6 months—so you may catch a mild or asymptomatic case more easily over time.
All vaccine types continue to protect well against hospitalization and death for longer than they protect against infection.
Key takeaway: Even as your risk of catching any infection rises over time, your chance of ending up hospitalized stays relatively low—provided you’re up to date on recommendations.
Several personal and external factors can speed up or slow down the waning of immunity:
Boosters are critical to restore and extend protection:
If it’s been more than 6 months since your last dose (or if you haven’t yet received a booster), you’re likely due. Talk with your healthcare provider about which booster is right for you.
Check your local health department or speak to a doctor for the most current advice.
If you’re feeling unwell or have COVID-like symptoms, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Staying proactive about your COVID-19 vaccinations—primary series and boosters—gives you the best chance at long-lasting protection, especially against severe outcomes. Speak to a doctor about any life-threatening or serious concerns and keep your vaccine record up to date.
(References)
* Lacson E Jr, Argyropoulos CP, Manley HJ, Aweh G, Chin AI, Salman LH, Hsu CM, Johnson DS, Weiner DE. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. J Am Soc Nephrol. 2021 Nov;32(11):2735-2742. doi: 10.1681/ASN.2021040432. Epub 2021 Aug 4. PMID: 34348908; PMCID: PMC8806103.
* Mizrahi B, Lotan R, Kalkstein N, Peretz A, Perez G, Ben-Tov A, Chodick G, Gazit S, Patalon T. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun. 2021 Nov 4;12(1):6379. doi: 10.1038/s41467-021-26672-3. Epub 2021 Nov 4. PMID: 34737312; PMCID: PMC8569006.
* Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Science. 2022 Aug 19;377(6608):821-822. doi: 10.1126/science.add2897. Epub 2022 Aug 18. PMID: 35981045.
* Gonzales MLAM, Dans LF, Tan-Lim CSC, Uy E, Cutiongco-Dela Paz E, Sulit MVV, Alejandria MM, Lansang MAD, Dans AL, Dator MA, Cordero CP, Pardilla GF. Durability and extent of protection of SARS-CoV-2 antibodies among patients with COVID-19 in Metro Manila, Philippines. Front Immunol. 2023;14:1190093. doi: 10.3389/fimmu.2023.1190093. Epub 2023 Jun 28. PMID: 37457735; PMCID: PMC10338854.
* Alroqi F, Barhoumi T, Masuadi E, Nogoud M, Aljedaie M, Abu-Jaffal AS, Bokhamseen M, Saud M, Hakami M, Arabi YM, Nasr A. Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines. J Infect Public Health. 2024 Apr;17(4):704-711. doi: 10.1016/j.jiph.2024.02.016. Epub 2024 Mar 1. PMID: 38479067.
* Marcos-Villar L, Perdiguero B, López-Bravo M, Zamora C, Sin L, Álvarez E, Sorzano CÓS, Sánchez-Cordón PJ, Casasnovas JM, Astorgano D, García-Arriaza J, Anthiya S, Borrajo ML, Lou G, Cuesta B, Franceschini L, Gelpí JL, Thielemans K, Sisteré-Oró M, Meyerhans A, García F, Esteban I, López-Bigas N, Plana M, Alonso MJ, Esteban M, Gómez CE. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium. Emerg Microbes Infect. 2024 Dec;13(1):2387906. doi: 10.1080/22221751.2024.2387906. Epub 2024 Aug 8. PMID: 39087555; PMCID: PMC11313003.
* Davis-Porada J, George AB, Lam N, Caron DP, Gray JI, Huang J, Hwu J, Wells SB, Matsumoto R, Kubota M, Lee Y, Morrison-Colvin R, Jensen IJ, Ural BB, Shaabani N, Weiskopf D, Grifoni A, Sette A, Szabo PA, Teijaro JR, Sims PA, Farber DL. Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues. Immunity. 2024 Dec 10;57(12):2895-2913.e8. doi: 10.1016/j.immuni.2024.10.003. Epub 2024 Nov 6. PMID: 39510068; PMCID: PMC11634668.
* Wang L, Wan J, He W, Wang Z, Wu Q, Zhou M, Fu ZF, Zhao L. IL-7 promotes mRNA vaccine-induced long-term immunity. J Nanobiotechnology. 2024 Nov 16;22(1):716. doi: 10.1186/s12951-024-02993-5. Epub 2024 Nov 16. PMID: 39550592; PMCID: PMC11568559.
* Ergun T. Urticarial vasculitis. Curr Opin Rheumatol. 2025 Jan 1;37(1):45-50. doi: 10.1097/BOR.0000000000001058. Epub 2024 Oct 11. PMID: 39600289.
* Zhou G, Dael N, Verweij S, Balafas S, Mubarik S, Oude Rengerink K, Pasmooij AMG, van Baarle D, Mol PGM, de Bock GH, Hak E. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024. Eur Respir Rev. 2025 Jan;34(175). doi: 10.1183/16000617.0222-2024. Epub 2025 Feb 19. PMID: 39971395; PMCID: PMC11836669.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.